Sanofi expects to resolve within the next five months certain manufacturing issues that derailed FDA’s approval of sarilumab for rheumatoid arthritis, which had been expected by its Oct. 30 Prescription Drug User Fee Act (PDUFA) goal date.
The company anticipates a resolution in time for the agency to approve its dupilumab treatment for atopic
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?